本文へ移動
cccskills
無料GitHub で公開

es-hcm-ugps1-iv-fluids-first-line

Recommends initiating intravenous isotonic saline hydration as initial management for hypercalcemia of malignancy (HCM) while awaiting antiresorptive therapy, with fluid rate adjusted according to cardiac function. Triggered when a clinician encounters a patient with HCM (e.g., serum calcium >12 mg/dL, symptoms of hypercalcemia) and seeks immediate measures before specific drugs are available.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md3.2 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Administer IV fluids as first‑line therapy while awaiting antiresorptives

STEP 1 — Gather Information

Collect serum calcium, symptom severity, cardiac history (known EF, signs of heart failure), volume status (JVP, peripheral edema), renal function (creatinine, urine output), and current medications.
Action: If data obtained, proceed to assess suitability for fluid resuscitation.

STEP 2 — Rule In / Rule Out

Is there evidence of volume overload or severe left ventricular dysfunction (e.g., pulmonary edema, EF < 30%, acute dyspnea at rest)?

  • No: Proceed with IV fluid resuscitation.
  • Yes: Avoid large bolus; consider a cautious fluid challenge (e.g., 250 mL NS over 1 h) with close monitoring or hold fluids and address overload first.
    Action: Based on the binary fork, decide whether to proceed with fluids or modify approach.

STEP 3 — Classify or Stratify

Stratify by cardiac function to tailor infusion rate:

  • Normal/mildly reduced EF ≥ 40%: Standard rate 200–500 mL/h.
  • Moderate reduction EF 30–39%: Reduced rate 100–200 mL/h.
  • Severe EF < 30% or overt HF: Minimal rate ≤100 mL/h, avoid bolus, monitor for overload.
    Action: Select the appropriate infusion rate based on this classification.

STEP 4 — Decide

Administer an initial isotonic saline bolus of 1–2 L (if no contraindication from Step 2), then continue at the rate determined in Step 3. Aim for urine output 100–150 mL/h, reassess serum calcium and volume status every 4–6 h, and prepare to start antiresorptive therapy (e.g., zoledronic acid or denosumab) as soon as available.
Action: Initiate fluids and monitor for response.

Clinical Guardrails / Mimics / Pitfalls

Do not give large fluid boluses in patients with known pulmonary edema, severe systolic dysfunction, or anuria; avoid excessive fluids in renal failure without monitoring; do not delay antiresorptives in severe HCM (SCa > 14 mg/dL) without adding calcitonin; avoid routine loop diuretics unless volume overload develops; monitor for hypokalemia and hypophosphatemia during hydration.

Concrete Clinical Example

A 68‑year‑old with metastatic lung cancer presents with fatigue, nausea, and serum calcium 13.8 mg/dL. Echocardiogram shows EF 50%, no pulmonary edema. Step 1: labs and vitals obtained. Step 2: no volume overload → proceed. Step 3: EF ≥ 40% → select 250 mL/h. Step 4: give 1 L NS bolus, then 250 mL/h targeting urine output 120 mL/h. Calcium falls to 11.5 mg/dL after 12 h; zoledronic acid is started thereafter.

Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する